Gina Battaglia | Authors


New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment Focus

April 03, 2020

PARP inhibitors following platinum-based chemotherapy as well as immunotherapy combinations have shown early signs of efficacy in metastatic pancreatic cancer with homologous recombination deficiency, according to data presented at the 2020 Gastrointestinal Cancers Symposium, held January 23 to 25 in San Francisco, California.

Immunotherapies Combined With Lung Cancer Treatments Could Be Practice Changing

October 06, 2016

Recent randomized clinical trials that have combined immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy for the treatment of patients with lung cancer have shown promising results for these combinations.